Search

Displaying results 5351 - 5360 of 10000 in total
  1. Drug

    Ponesimod

    go.drugbank.com/drugs/DB12016
    ApprovedInvestigational

    [A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod]. … [A232079] Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and so more selective modulators were developed.

  2. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators.

  3. Drug

    Darbepoetin alfa

    go.drugbank.com/drugs/DB00012
    ApprovedInvestigational

    Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

    Products: ARANESP 20UG FS MIT ANS, ARANESP 100UG FS MIT ANS
  4. Drug

    Zibrofusidic acid

    go.drugbank.com/drugs/DB20799
    Investigational

    Zibrofusidic acid has a monoisotopic molecular weight of 594.26 Da. … Zibrofusidic acid is a small molecule drug.

  5. Drug

    Evixapodlin

    go.drugbank.com/drugs/DB21520
    Investigational

    Evixapodlin has a monoisotopic molecular weight of 690.22 Da. … Evixapodlin is a small molecule drug.

  6. Drug

    Abarelix

    go.drugbank.com/drugs/DB00106
    ApprovedWithdrawn

    It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.

  7. Drug

    Metharbital

    go.drugbank.com/drugs/DB00463
    ApprovedWithdrawn

    Metharbital is a barbiturate anticonvulsant, similar to phenobarbital, marketed as Gemonil by Abbott Laboratories. It was patented in 1905 by Emil Fischer of Merck.

  8. Drug

    Vevorisertib

    go.drugbank.com/drugs/DB21481
    Investigational

    Vevorisertib has a monoisotopic molecular weight of 586.32 Da. … Vevorisertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Vevorisertib is a serine/threonine kinase inhibitor.

  9. Drug

    Picafibrate

    go.drugbank.com/drugs/DB19574
    Experimental

    Picafibrate has a monoisotopic molecular weight of 362.1 Da. … Picafibrate is a small molecule drug.

  10. Drug

    Tiafibrate

    go.drugbank.com/drugs/DB19874
    Experimental

    Tiafibrate has a monoisotopic molecular weight of 686.23 Da. … Tiafibrate is a small molecule drug.